MarkBernardEffronMD

PubMed

• 1 citations
  Achievement of LDL-C <55 mg/dL among US adults: Findings from the cvMOBIUS2 registry.
  Ann Marie Navar, Nishant P Shah, Peter Shrader, Laine E Thomas, Zahid Ahmad
  American Heart Journal. 2025-01-01
• 1 citations
  Platelet FcγRIIa as a Marker of Cardiovascular Risk After Myocardial Infarction.
  David J Schneider, Sean R McMahon, Dominick J Angiolillo, Alexander Fanaroff, Homam Ibrahim
  Journal of the American College of Cardiology. 2024-10-29
• Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinica...
  Catherine P Benziger, Amanda Stebbins, Lisa M Wruck, Mark B Effron, Guillaume Marquis-Gravel
  JAMA Cardiology. 2024-09-01

Journal Articles

• Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary in...  
  Faggioni M, Baber U, Chandrasekhar J, Sartori S, Claessen BE, Rao SV, Vogel B, Effron MB, Poddar K, Farhan S, Kini A, Weintraub W, Toma C, Sorrentino S, Weiss S, Snyde..., International J Cardiol, 1/1/2019
• The waxing and waning of antithrombotic therapy in cardiovascular disease � Where is the moon now?  
  Effron MB, Gibson CM, Progr Cardiovasc Dis, 1/1/2018
• Dual (anticoagulant plus single antiplatelet) vs triple (anticoagulant plus dual antiplatelet) antithrombotic therapy - "Real world" experience  
  Effron MB, Gibson CM, Progr Cardiovasc Dis, 1/1/2018
•  
  Fanaroff AC, Kaltenbach LA, Peterson ED, Akhter MW, Effron MB, Henry TD, Wang TY, J Am Heart Assoc, 1/1/2018
• The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary int...  
  Effron MB, Wang TY, Fonarow GC, Henry TD, Zettler M, Baker B, McCoy L, Peterson E, Catheterization Cardiovasc Intv, 1/1/2018
• Glycoprotein IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: Insights from the TRANSLATE ACS study  
  Ibrahim H, Kaltenbach LA, Hess CN, Recchia T, Effron MB, Stone GW, Wang TY, Catheter Cardiovasc Interv, 1/1/2018
• Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study  
  Chandrasekhar J, Baber U, Sartori S, Aquino M, Kini AS, Rao S, Weintraub W, Henry TD, Farhan S, Vogel B, Sorrentino S, Ge Z, Kapadia S, Muhlestein JB, Weiss S, Strauss..., Can J Cardiol, 1/1/2018
• One-year clinical effectiveness comparison of prasugrel with ticagrelor: Results from a retrospective observational study using an integrated claims database  
  Effron MB, Nair KV, Molife C, Keller SY, Page II RL, Simeone JC, Murphy B, Nordstrom BL, Zhu Y, McCollam PL, Vetrovec GW, Am J Cardiovasc Drugs, 1/1/2018
• Multivessel versus culprit vessel�only percutaneous coronaryintervention among patients with acute myocardial infarction: Insights from the TRANSLATE-ACS observational...  
  Ibrahim H, Sharma PK, Cohen DJ, Fonarow GC, Kaltenbach LA, Effron MB, Zettler ME, Peterson ED, Wang TY, J Am Heart Assoc, 1/1/2017
• Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical p...  
  Bagai A, Peterson ED, McCoy LA, Effron MB, Zettler ME, Stone GW, Henry TD, Cohen DJ, Schulte PJ, Anstrom KJ, Wang TY, Am Heart J, 1/1/2017
• Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosp...  
  Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, Baker BA, Messenger JC, Cohen DJ, Wang TY; TRANSLATE-ACS Investigators, Am Heart J, 1/1/2017
• Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: ...  
  Baber U, Sartori S, Aquino M, Kini A, Kapadia S, Weiss S, MD, Strauss C, Muhlestein JB, Toma C, Rao SV, DeFranco A, Poddar KL, Chandrasekhar J, Weintraub W, Henry TD, ..., Am Heart J, 1/1/2017
• Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from ...  
  Chandrasekhar J, Usman Baber U, Samantha Sartori S, Michela Faggioni M, Melissa Aquino M, Annapoorna Kini A, William Weintraub W, Sunil Rao S, Samir Kapadia S, Sandra ..., Catheter Cardiovasc Interv, 1/1/2017
• Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coro...  
  Baber U, Chandrasekhar J, Sartori S, Aquino M, Kini AS, Kapadia S, Weintraub W, Muhlestein JB, Vogel B, Faggioni M, Farhan S, Sandra Weiss S, Strauss C, Toma C, De Fra..., J Am Coll Cardiol Intv, 1/1/2017
• Accuracy of medical claims for identifying cardiovascular and bleeding events after myocardial infarction : A secondary analysis of the TRANSLATE-ACS study  
  Guimaraes PO, Krishnamoorthy A, Kaltenbach LA, Anstrom KJ, Effron MB, Mark DB, McCollam PL, Davidson-Ray L, Peterson ED, Wang TY, JAMA Cardiol, 1/1/2017
• Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention treated with clopidogrel or prasugrel  
  Bae JP, Faries DE, Ernst FR, Lipkin C, Zhao Z, Moretz C, Lieu HD, Effron MB, Am J Health-Syst Pharm, 1/1/2016
• Real-World comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention in the United States  
  Larmore C, Effron MB, Molife C, DeKovenM , Zhu Y, Lu J, Karkare S, Lieu HD, Lee WC, Vetrovec GW, Catheter Cardiovasc Interv, 1/1/2016
• Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From ...  
  Fosbol EL, Ju C, Anstrom KJ, Zettler ME, Messenger JC, Waksman R, Effron MB, Baker BA, Cohen DJ, Peterson ED, Wang TY, Circ Cardiovasc Interv, 1/1/2016
• Unplanned inpatient and observation rehospitalizations after acute myocardial infarction insights from the treatment with adenosine diphosphate receptor inhibitors: Lo...  
  Hess CN, Wang TY, McCoy LA, Messenger JC, Effron MB, Zettler ME, Henry TD, Peterson ED, Fonarow GC, Circulation, 1/1/2016
• Impact of bleeding on quality of life in patients on DAPT: Insights from TRANSLATE-ACS  
  Amin AP, Wang TY, McCoy L, Bach RG, Effron MB, Peterson ED, Cohen DJ, J Am Coll Cardiol, 1/1/2016
• How reliable are patient-reported rehospitalizations? Implications for the design of future practical clinical studies  
  Krishnamoorthy A, Peterson ED, Knight JD, Anstrom KJ, Effron MB, Zettler ME, Davidson-Ray L, Baker BA, McCollam PL, Mark DB, Wang TY, J Am Heart Assoc, 1/1/2016
• Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate...  
  Jackson LR 2nd, Peterson ED, McCoy LA, Ju C, Zettler M, Baker BA, Messenger JC, Faries DE, Effron MB, Cohen DJ, Wang TY, J Am Heart Assoc, 1/1/2016
• Comparing inverse probability weighting and instrumental variable approaches for the evaluation of adenosine diphosphate receptor inhibitors  
  Federspiel JJ, Anstrom KJ, Xian Y, McCoy LA, Effron MB, Faires DE, Zettler M, Mauri L, Yeh RW, Peterson ED, Wang TY, JAMA Cardiol, 1/1/2016
• Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Ins...  
  Vora AN, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Faries DE, Zettler ME, Fonarow GC, Baker BA, Stone GW, Wang TY, J Am Heart Assoc, 1/1/2016
• Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiv...  
  Molife C, Frech-Tamas F, DeKoven M, Effron MB, Karkare S, Zhu Y, Larmore C, Lu J, McCollam P, Marrett E, Vetrovec GW, J Med Econ, 1/1/2015
• Join now to see all

Books/Book Chapters

• Scientific American Medicine. 
  Chapter: Circulatory shock. 
  Page 1 - 11Effron MB, Chernow BEditors: Rubenstein E, Federman DD.1992

Abstracts/Posters

• Can Medical Claims accurately assess cardiovascular and bleeding events in an all-aged post-myocardial infarction population? Insights from the TRANSLATE-ACS study.
  Guimaraes PO, Krishnamoorthy A, Kaltenbach LA, Anstrom KJ, Effron MB, Mark DB, McCollam PL, Davidson-Ray L, Peterson ED, Wang TY, Circ Cardiovasc Qual Outcomes, 1/1/2017
• Use of potent P2Y12 Inhibitors in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes.
  Faggioni M, Baber U, Chandrasekhar J, Vogel B, Sartori S, Aquino M, Kini A, Weintraub W, Kapadia S, Weiss S, Strauss C, Snyder C, Toma C, Muhlestein J, DeFranco AC, Ef..., J Am Coll Cardiol, 1/1/2017
• Antiplatelet therapy changes for MI patients with recurrent ischemic events: Insights into contemporary practice from the TRANSLATE-ACS study.
  Fanaroff AC, Kaltenbach LA, Peterson E, Akhter M, Effron MB, Henry T, Wang T, J Am Coll Cardiol, 1/1/2017
• Contemporary patterns of GP IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: Insights from the TRANSLATE ACS study.
  Ibrahim H, McCoy L, Hess C, Akhter M, Effron MB, Stone G, Wang T, J Am Coll Cardiol, 1/1/2017
• Outcomes by Total Stent Length in ACS PCI with Second Generation Drug-Eluting Stents: Results from the PROMETHEUS Study
  Mahajan A, Chandrasekhar J, Sartori S, Baber U, Vogel B, Sorrentino S, Snyder C, Kini A, Rao S, Kapadia S, Henry T, Effron M, Weintraub W, Weiss S, Strauss C, DeFranco..., J Am Coll Cardiol, 1/1/2017
• Associations between Stent Diameter and Clinical Outcomes in ACS PCI Using Second Generation Drug-Eluting Stents: From the PROMETHEUS Study.
  Qadeer A, Chandrasekhar J, Baber U, Sartori S, , Ge Z, Farhan S, Sharma M, Kini A, Rao S, Kapadia S, Henry T, Muhlstein J, Effron M, Weintraub W, Weiss S, Strauss C, D..., J Am Coll Cardiol, 1/1/2017
• Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS atudy.
  Vogel B, Baber U, Sartori S, Chandrasekhar J, Farhan S, , Sorrentino S, Kini A, Weintraub W, Rao S, Kapadia S, Weiss S, Strauss C, Toma C, Muhlestein J, DeFranco AC, E..., J Am Coll Cardiol, 1/1/2017
• Impact and use of prasugrel versus Clopidogrel as a function of age among patients with acute coronary syndrome undergoing percutaneous coronary intervention.
  Chandrasekhar J, Baber U, Sartori S, Aquino M, Henry T, Rao S, Snyder C, Weintraub W, Effron M, Pocock S, Keller S, Kini A, Strauss C, Mehran R, Kapadia S, Eur Heart J, 1/1/2016
• The impact of DAPT clinical risk score and ACUITY bleeding risk score in determining adverse clinical outcomes following PCI: results from the PROMETHEUS study.
  Chandrasekhar J, Baber U, Sartori1 S, Rao S, Henry T, Weintraub W, Effron M, Danias G, Keller S, Weiss S, Defranco A, Muhlestein JB, Kapadia, Pocock S, Mehran R, Eur Heart J, 1/1/2016
• Evaluation of thienopyridine prescription in real world PCI by DAPT and ACUITY clinical risk scores: results from the PROMETHEUS study.
  Chandrasekhar J, Faggioni M, Baber U, Sartori S, Levine H, Dangas G, Rao S, Effron M, Baker B, Pocock S, Kini A, Muhlestein B, Henry T, Weintraub W, Mehran R, Eur Heart J, 1/1/2016
• Patterns of use of prasugrel or clopidogrel in elderly patients in the �real world� from the PROMETHEUS registry.
  Effron M, Baber U, Keller S, Weintraub W, Henry T, Kapadia S, Rao S, Strauss C, Baker B, Mehran R, Eur Heart J, 1/1/2016
• Prevalence and outcomes of prasugrel versus clopidogrel in patients with and without diabetes following percutaneous coronary intervention for acute coronary syndrome.
  Faggioni M, Chandrasekhar J, Baber U, Sartori S, Aquino M, Rao S, Weintraub W, Effron M, Baker B, Danias G, Pocock S, Kapadia S, Toma C, Mehran R, Henry T, Eur Heart J, 1/1/2016
• Prevalence of prasugrel use and associations between type of acute coronary syndrome and 1-year clinical outcomes.
  Asim Rafique A, Chandrasekhar J, Baber U, Sartori S, Aquino M, Kapadia S, Rao S, Muhlestein JB, Toma C, Strauss C, Weintraub W, Weiss S, DeFranco A, Pocock S, Effron M..., J Am Coll Cardiol, 1/1/2016
• Relationship between anemia, prasugrel use and clinical outcomes in contemporary percutaneous coronary intervention for acute coronary syndromes.
  Chandrasekhar J, Baber U, Sartori S, Aquino M, Faggioni M, Vogel B, Farhan M, Muhlestein JB, Strauss C, Toma C, Weintraub W, Weiss S, DeFranco A, Kini A, Effron M, Bak..., J Am Coll Cardiol, 1/1/2016
• Predictors of optimal medical therapy on discharge after percutaneous coronary intervention for acute coronary syndrome: An analysis of the PROMETHEUS registry.
  Farhan S, Baber U, Chandrasekhar J, Sartori S, Aquino M, Giustino G, Kini A, Weintraub W, Rao S, Kapadia S, Weiss S, Strauss C, Toma C, Muhlestein JB, DeFranco A, Effr..., J Am Coll Cardiol, 1/1/2016
• Incidence, predictors and impact of stroke after percutaneous coronary intervention for acute coronary syndromes: results from the PROMETHEUS registry.
  Giustino G, Baber U, Sartori S, Aoi S, Aquino M, Chandrasekhar J, Weintraub W, Rao S; Weiss S, Henry T, Kapadia S. Poddar K, DeFranco A, Muhlestein J, Toma C, Effron M..., J Am Coll Cardiol, 1/1/2016
• Use of clopidogrel versus prasugrel in patients undergoing percutaneous coronary intervention: factors influencing real-world therapeutic decision-making.
  Salianski O, Baber U, Sartori S, Aoi S, Aquino M, Chandrasekhar J, Kini A, Rao S, Weintraub W, Weiss S, Henry T, Kapadia S, Poddar K, DeFranco A, Muhlestein J, Toma C,..., J Am Coll Cardiol, 1/1/2016
• Sex-related differences in outcomes after percutaneous coronary intervention (PCI) in patients with diabetes presenting with acute coronary syndrome (ACS): Results fro...
  Vogel B, Baber U, Sartori S, Chandrasekhar J, Aquino M, Farhan F, Kini A, Weintraub W, Rao S, Kapadia S, Weiss S, Strauss C, Toma C, Muhlestein JB, DeFranco A, Effron ..., J Am Coll Cardiol, 1/1/2016
• Predictors of 1 year net adverse cardiovascular events (NACE) among ACS patients undergoing PCI with clopidogrel or prasugrel: analysis from the PROMETHEUS registry.
  Wayangankar SA, Baber U, Poddar K, Weiss S, Henry T, Muhlestein J, Baker B, Mehran R, Kini A, Sartori S, Rao S, Weintraub W, Strauss C, DeFranco A, Toma C, Keller S, E..., J Am Coll Cardiol, 1/1/2016
• ADP receptor inhibitor therapy use beyond 12 months in community practice: Results from the TRANSLATE-ACS registry.
  Hansen JD, McCoy LA, Cohen DJ, Henry TD, Gregg Fonarow GC, Effron MB, Zettler ME, Baker BA, Peterson ED, Wang TY, Circulation, 1/1/2015
• Switching of ADP receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the TRANSLATE-ACS observational study.
  Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, Baker BA, Messenger JC, Cohen DJ, Wang TY, Circulation, 1/1/2015
• Temporal associations between myocardial infarction, major bleeding and mortality risk in ACS patients undergoing PCI: Insights from the PROMETHEUS cohort.
  Baber U, Chao J, Chandrasekhar J, Sartori S, Aquino M, Kini A, Rao S, Weintraub W, Weiss S, Strauss C, Kapadia S, Henry T, DeFranco A, Muhlestein B, Toma C, Pocock S, ..., J Am Coll Cardiol, 1/1/2015
• Impact of prasugrel versus clopidogrel in smokers and non-smokers undergoing PCI for ACS: Results from the PROMETHEUS Study.
  Chandrasekhar J, Baber U, Sartori S, Aquino M, DeFranco A, Muhlestein JB, Weiss S, Henry TD, Effron MB, Strauss CE, Keller SY, Baker BA, Weintraub W, Chao J, Poddar KL..., J Am Coll Cardiol, 1/1/2015
• Impact of prasugrel versus clopidogrel in ACS patients undergoing PCI with short or long stents: Results from the PROMETHEUS Study.
  Chandrasekhar J, Baber U, Sartori S, Aquino M, Henry TD, Kini A, Kapadia S, Rao S, Weiss S, Muhlestein JB, Poddar KL, Baker BA, Keller SY, Effron MB, Chao J, Strauss C..., J Am Coll Cardiol, 1/1/2015
• Effect of prasugrel versus clopidogrel in ACS patients with high or low BMI undergoing PCI: Results from the PROMETHEUS Study.
  Chandrasekhar J, Baber U, Sartori S, Aquino M, Strauss CE, Muhlestein JB, Weiss S, Effron MB, Keller SY, Baker BA, Chao J, Rao S, Kapadia S, Poddar KL, DeFranco A, Kin..., J Am Coll Cardiol, 1/1/2015
• Join now to see all

Lectures

• Optimal Duration of P2Y12 Inhibitor Therapy After Stenting: Is There A Clear Answer? 
  Medical College of Virginia, Richmond, VA, 2014; Ochsner Health System, New Orleans, LA, 2015 - 1/18/2015
• Antithrombotic Therapy in the Treatment of Acute Coronary Syndrome 
  Charleston, WV - 1/17/2014
• Safe PCI for Women: View from the Pharmaceutical Industry 
  White Oak, MD - 1/29/2013
• Drug and device safety: Can we work from common ground? 
  White Oak, MD - 1/4/2012
• Intracranial, GI, & surgical bleeding with more potent agents: A view from industry 
  White Oak, MD - 1/7/2011
• Bleeding, procedural outcomes and other key endpoints/variables - A drug industry view 
  White Oak, MD - 1/23/2010
• Antiplatelet therapy: a paradigm for personalized medicine 
  Krannert Institute of Cardiology, Indiana University School of Medicine - 1/8/2010
• Prasugrel Overview 
  Snowmass, CO - 1/8/2009
• Full disclosure: Trial Registries and Its Effect on Phase IV Studies 
  Philadelphia, PA - 1/19/2005
• Reperfusion Therapy in ST Eleavation Myocardial Infarction (STEMI) - Fibrinolysis, Facilitated PCI, or PCI with Adjunctive Therapy? 
  University of Massachusetts Medical Center, Worcester, MA - 1/5/2005
• The New ACC/AHA STEMI Guidelines - Role of Adjunctive Pharmacotherapeutics for Primary Percutaneous Intervention (PCI) 
  St Vincent Hospital, Worcester, MA - 1/20/2004
• Drotrecogin alfa (activated) in the Treatment of Severe Sepsis 
  Westchester Medical Center, Valhalla, NY - 1/19/2004
• Recent Advances in Therapy Using Glycoprotein IIb/IIIa Receptor Inhibitors 
  Albert Einstein Medical Center, Philadelphia, PA - 1/3/2000
• New Pharmacological Approaches Adjunctive to Interventional Coronary Procedures 
  Jerusalem, Israel - 1/30/1999
• Insights into Abciximab: The Lilly/Centocor Experience 
  Washington, DC - 1/22/1999
• Efficacy and Cost Effectiveness of GP IIb/IIIa Inhibitors 
  Multiple Locations, 1999 - 1/1/1999
• Cost Effectiveness of GP IIb/IIIa Inhibitors 
  Jerusalem, Israel - 1/1/1999
• The CADILLAC Trial; Preliminary Results 
  Jerusalem, Israel - 1/1/1999
• Abciximab Update 
  Latter Day Saints Hospital, Salt Lake City, UT - 1/21/1998
• Use of Platelet Glycoprotein IIb/IIIa Inhibitors in the Treatment of Coronary Artery Disease 
  Tallahassee Memorial Regional Medical Center, Tallahassee, FL, 1997; West Virginia University School - 1/15/1998
• IIb/IIIa receptor inhibitors. 
  The West Pennsylvania Hospital, Pittsburgh, PA - 1/29/1997
• Recent trends in inotrope therapy. 
  Madras, India - 1/6/1997
• Abciximab, a new potent antiplatelet agent. 
  Multiple Locations, 1997 - 1/5/1997
• Antiplatelet therapy in acute coronary syndromes. 
  Lankenau Hospital, Wynnewood, PA, 1997; Sinai Hospital of Baltimore, Baltimore, MD, 1997 - 1/3/1997
• Use of c7E3 in coronary angioplasty. 
  Multiple Locations, 1995, 1996 - 1/23/1996
• Join now to see all

Other

• Important Trial Results for Interventional Cardiology From TCT 2017 and AHA 2017. 
  Vetrovec GW, Effron MB, Ellenbogen KA, Angiolillo DJ, Berger PB, Gurbel PA, Shah KB
  http://www.acc.org/latest-in-cardiology/articles/2018/01/22/09/02/important-trial-results-for-interventional-cardiology-from-tct-2017-and-aha-2017
  1/22/2018
• Clot dissolving drugs 
  Effron MB, The Heart of the Matter-Radio Program, Series 210A, National Emergency Medicine Association
  1/1/1990